Right now we don’t have any job openings, volunteer opportunities, or upcoming events.
Log in or sign up to be among the first to know when new openings or events are added!
The TB Alliance is an international product
development partnership (PDP) created to accelerate the development and
adoption of urgently needed new anti-tuberculosis (TB) drugs.
Based in New York City, the TB
Alliance also operates a satellite office in Pretoria, South Africa, focused on clinical trials management.
The TB Alliance is preeminent in
the TB drug development field and is pursuing faster, simpler treatments for
all forms of TB through the innovative PDP business model that bridges the
expertise and functionality of industry with academic and public sector
interests to meet a major unmet global health need.
With an annual operating budget
of approximately $60 million, the TB Alliance leads the advancement of the most
comprehensive R&D portfolio of TB drug candidates in history. Currently, a
portfolio of more than 20 projects spans from target validation to Phase III
clinical development. Additionally, the TB Alliance drives efforts to ensure
regulatory approval, country adoption of new regimens, and widespread
availability of new drug regimens to patients.
Tuberculosis kills nearly 1.5
million each year. Yet, current treatments are antiquated, inadequate, and
excessively burdensome. Long, demanding treatment schedules prove too much for
many patients, leading to the emergence of multi- and extensively-
drug-resistant TB (MDR-TB and XDR-TB), which are exponentially more expensive
and difficult to treat.